目的 探讨脑心通胶囊联合奥拉西坦胶囊治疗脑出血恢复期的临床疗效。方法 将2023年8月—2025年12月衡水市人民医院收治的80例脑出血恢复期患者作为研究对象，按照随机数字表法将患者分为对照组和治疗组，每组40例。对照组口服奥拉西坦胶囊，2粒/次，3次/d。治疗组在对照组基础上口服脑心通胶囊，4粒/次，3次/d。两组持续治疗8周。比较两组患者的临床治疗效果、美国国立卫生研究院卒中量表（NIHSS）评分、Barthel指数（BI）评分、简化版的改良Rankin量表（smRSq）评分、Fugl-Meyer运动功能评分（FMA）和血清指标。结果 治疗组的总有效率为90.00%，对照组的总有效率为72.50%，组间差异有统计学意义（P＜0.05）。两组治疗后的NIHSS、smRSq评分显著降低，BI、FMA评分显著升高（P＜0.05）；治疗组治疗后的NIHSS、smRSq评分低于对照组，BI、FMA评分高于对照组（P＜0.05）。两组治疗后的血清高迁移率族蛋白B1（HMGB-1）、基质金属蛋白酶-2（MMP-2）、神经元特异性烯醇化酶（NSE）水平均显著降低（P＜0.05），治疗组治疗后血清HMGB-1、MMP-2、NSE水平明显低于对照组（P＜0.05）。结论 脑心通胶囊联合奥拉西坦胶囊可提高脑出血恢复期的疗效，改善神经功能和日常生活自理能力、提高整体功能和运动功能，减轻神经炎性损伤。

Objective To investigate the clinical efficacy of Naoxintong Capsules combined with Oxiracetam Capsules in treatment of cerebral hemorrhage during recovery phase. Methods A total of 80 patients with cerebral hemorrhage during recovery phase admitted to Hengshui People’s Hospital from August 2023 to December 2025 were selected as the study subjects. They were divided into control group and treatment group according to the random number table method, with 40 cases in each group. The control group was received oral Oxiracetam Capsules at a dosage of 2 capsules per dose, 3 times daily. The treatment group received oral Naoxintong Capsules in addition to the treatment given to the control group, at a dosage of 4 capsules per dose, 3 times daily. Two groups were treated for 8 weeks. The clinical therapeutic effects, NIHSS scores, Barthel Index (BI) scores, simplified modified Rankin Scale (smRSq) scores, Fugl-Meyer Motor Assessment (FMA) scores, and serum indicators were compared between two groups. Results The total effective rate of the treatment group was 90.00%, while the total effective rate of the control group was 72.50%, and the difference between groups was statistically significant (P< 0.05). The NIHSS and smRSq scores significantly decreased after treatment in two groups, while the BI and FMA scores significantly increased (P< 0.05). The NIHSS and smRSq scores of the treatment group were lower than those of the control group after treatment, while the BI and FMA scores were higher than those of the control group (P < 0.05). After treatment, the serum levels of high mobility group protein B1 (HMGB-1), matrix metalloproteinase-2 (MMP-2), and neuron specific enolase (NSE) in two groups were significantly reduced (P < 0.05). The serum levels of HMGB-1, MMP-2, and NSE in the treatment group were significantly lower than those in the control group after treatment (P < 0.05). Conclusion The combination of Naoxintong Capsules and Oxiracetam Capsules can improve the therapeutic effect in treatment of cerebral hemorrhage during recovery phase, enhance neurological function and daily living self-care ability, improve overall function and motor function, and reduce neuroinflammatory injury.

R971

河北省卫生健康委员会项目（20261161）